Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: Results from two large independent cohorts

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Humphreys, Jennifer H ^a   van Nies, Jessica ^b   Chipping, Jackie ^c   Marshall, Tarnya ^d   Mil, Helm van ^b   Symmons, Deborah ^a,e   Verstappen, Suzanne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CITRULLINATED PROTEIN ANTIBODY; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SEROLOGY; SMOKING; ARTHRITIS, RHEUMATOID; BLOOD; MIDDLE AGED; SURVIVAL RATE; TRENDS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; CITRULLINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORTALITY; RHEUMATOID FACTOR; SURVIVAL RATE;

EID: 84924293329     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0483-3     Document Type: Article

References (30)

1. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P: Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006, 45:478-480.
2. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F: Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004, 63:1587-1593.
3. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749.
4. Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y: Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 2007, 26:1627-1633.
5. Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, Van De Stadt RJ, Van Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann D: Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:558-563.
6. Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, Filippini M, Tampoia M, Afeltra A, Sebastiani G, Alpini C, Bini V, Bistoni O, Alunno A, Gerli R: Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther 2013, 15:R16.
7. Mjaavatten MD, van der Heijde D, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK: The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res Ther 2010, 12:R76.
8. Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, Giannakou A, Galanopoulou VK: Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Clin Rev Allergy Immunol 2008, 34:11-15.
9. Shiozawa K, Kawasaki Y, Yamane T, Yoshihara R, Tanaka Y, Uto K, Shiozawa S: Anticitrullinated protein antibody, but not its titer, is a predictor of radiographic progression and disease activity in rheumatoid arthritis. J Rheumatol 2012, 39:694-700.
10. Ursum J, Bos WH, van Dillen N, Dijkmans BA, Van Schaardenburg D: Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010, 12:R8.
11. Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EW, van der Helm-van Mil AH, Van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA: Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2014, 73:720-726.
12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
13. Sokka T, Abelson B, Pincus T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008, 26:S35-S61.
14. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP: Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
15. Sokka T, Hakkinen A, Krishnan E, Hannonen P: Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004, 63:494-497.
16. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
17. Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V: Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010, 69:1649-1654.
18. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, Barton A: Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58:359-369.
19. van der Linden MP, Batstra MR, Bakker-Jonges LE, Detert J, Bastian H, Scherer HU, Toes RE, Burmester GR, Mjaavatten MD, Kvien TK, Huizinga TW, van der Helm-van Mil AH: Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum 2011, 63:1190-1199.
20. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ: The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994, 33:735-739.
21. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH: Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011, 50:93-100.
22. Liang KP, Kremers HM, Crowson CS, Snyder MR, Therneau TM, Roger VL, Gabriel SE: Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2469.
23. Sihvonen S, Korpela M, Mustila A, Mustonen J: The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005, 32:2089-2094.
24. Landmann T, Kehl G, Bergner R: The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 2010, 29:1449-1453.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
26. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewe R, Kvien TK: High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217.
27. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V: Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:311-316.
28. Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjorneboe O, Kvien TK: Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study. J Rheumatol 2011, 38:2336-2341.
29. Burr ML, Viatte S, Bukhari M, Plant D, Symmons DP, Thomson W, Barton A: Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Res Ther 2012, 14:R109.
30. Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, Smolen JS, Steiner G: Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2010, 69:169-174.